You are here: Industry Insights > Xpovio

News List

Antengene Announces the Approval of First-in-Class Oral XPO1 Inhibitor Selinexor in South Korea for the Treatment of Relapsed or Refractory Multiple Myeloma and Diffuse Large B-Cell Lymphoma firstwordpharma
August 02, 2021
Antengene Corporation Limited today announced that through a priority review process, the South Korean Ministry of Food and Drug Safety (MFDS) has approved the company's NDA for the Orphan Drug-designated first-in-class oral inhibitor of XPO1.
Antengene Announces the Acceptance of ATG-010 (Selinexor) NDA by the NMPA for the Treatment of rrMM prnasia
January 28, 2021
Antengene Corporation Limited, a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in class therapeutics in hematology and oncology, announced that the ...
FDA Approves XPOVIO for Multiple Myeloma americanpharmaceuticalreview
January 07, 2021
Karyopharm Therapeutics announced the U.S. Food and Drug Administration (FDA) has approved XPOVIO® (selinexor), the Company's first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) medicine, in combination with bortezomib and dexamethasone ...
Antengene Announces its U.S. Partner, Karyopharm Therapeutics Inc., has received FDA Approval of XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy prnasia
December 21, 2020
Antengene Corporation Limited today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) submitted by its partner Karyopharm Therapeutics Inc. for oral XPOVIO® (selinexor, ATG-010) ...
Xpovio hits endpoints in Phase III multiple myeloma trial pharmatimes
March 06, 2020
Karyopharm has announced positive top-line results from the randomised Phase III BOSTON study of Xpovio (selinexor).
Xpovio With Dexamethasone Approved for Refractory Multiple Myeloma drugs
July 10, 2019
Xpovio With Dexamethasone Approved for Refractory Multiple Myeloma.
Karyopharm’s Xpovio nabs myeloma nod despite checkered past fiercepharma
July 09, 2019
Karyopharm finally got its much-needed first commercial approval for a drug that has stirred up safety concerns—and suffered plenty of speed bumps—along the way. Now the company must cope with a limited FDA nod, and with a brand-new marketing chief to boo
FDA Approves Xpovio (selinexor) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma drugs
July 04, 2019
FDA Approves Xpovio (selinexor) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma.